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Introduction
In the middle of the nineteenth century Rudolf Virchow described for the first time neuroglia as a connective tissue that glued nervous elements together [1] . Later studies of Camillo Golgi allowed to recognise the cellular nature of glia [2, 3] , then identified as a group of cells distinguishable from neurons. Central nervous system (CNS) glial cells encompass oligodendrocytes, the myelin forming cells, gives rise to finely branching processes. The fibrous astrocytes are mainly localised along myelinated fiber tracts in the white matter and are characterized by many long fiber-like processes [4, 5] . The intermediate filament glial fibrillary acid protein (GFAP) is the specific astrocyte marker, even though the variability of the GFAP expression in mature astrocytes in healthy CNS can limit its in vivo use [6, 7] . The dense network of specialized, finely branched processes extending from the cell body allows astrocytes to contact and ensheath cerebral blood vessels and neuronal synapses whose development and functionality are strictly regulated by astrocytes. In this review we summarize general astrocyte functions in the healthy CNS and provide some examples of neurological diseases whose pathogenic mechanisms directly alter astrocyte physiology. We will then discuss in more detail the genetic leukodystrophies in which a primary pathogenic role for astrocytes has been described and the possibility to target these cells for therapeutic intervention.
Astrocytes in CNS physiology
Evidence accumulated over the last 20 
Astrocytes and neurons: the synaptic domain (Figure 1)
Astrocyte-neuron relationships start during development when astrocytes regulate neurogenesis by guiding and supporting neuronal migration, survival and process extension [8] . Astrocytes participate in the formation, maintenance and remodelling of synapses mainly through release of trophic factors such as brain-derived neurotrophic factor Figure 1 . Astrocyte-neuron relationships. Astrocytes are involved in the uptake and release of neurotransmitters, trophic factors and energy substrates for neurons and in the control of ion homeostasis. Astrocytes respond with Ca 2+ elevations to neurotransmitters released during synaptic activity and, in turn, control neuronal excitability and synaptic transmission through the Ca2 + -dependent release of gliotransmitters such as glutamate, ATP, GABA and D-serine. The uptake of the neurotransmitter glutamate from the synaptic cleft by astrocytes occurs via Na + -dependent excitatory amino acid transporters (EAATs). Glutamate is then converted into glutamine by glutamine synthetase (GS) and released back to neurons where it is converted to glutamate by glutaminase. Na + , K + -ATPase provides the Na + -mediated driving force for glutamate uptake. Trophic factors like BDNF, GDNF, NGF, IGF and thrombospondin, produced and released by astrocytes regulate synapse formation, maintenance and remodelling. Glutamatergic activation induces lactate release from astrocytes via monocarboxylate transporters (MCT). Astrocytes also control water and ion exchange in the synaptic cleft through water (AQP4) and ion (Kir4. -dependent vesicular release ( [25] and references therein) but also via other mechanisms (reviewed by [26, 27] ). Release of gliotransmitters is also driven by a volume regulatory response stimulated by osmotic imbalance conditions following the release of osmotically active solutes from the neuronal cytoplasm into the extracellular space [27] .
These findings have led to build-up a new model of neuron-glia inter-communication, the so called "tripartite synapse", comprising the pre-and post-synaptic neurons and the astrocyte, where the latter integrates neuronal inputs and modulates synaptic activity [22] .
Other soluble factors produced by astrocytes in vitro and in vivo, such as neurosteroids [28] , growth factors and cytokines [29] , can also influence synaptic activity.
Astrocytes also support brain activity by supplying neurons with energy substrates.
They contribute to take up glucose, the primary source of energy for the brain, from the blood circulation and to deliver it to neurons. Apart from neurons which mainly rely on oxidative metabolism, astrocytes rely more on glycolytic metabolism to generate ATP and lactate from glucose [30, 31] . Glucose enters astrocytes via specific glucose transporters (GLUT) and its degradation to lactate represents the main energy source for neurons, particularly during intense neuronal activity. In the "astrocyteneuron lactate shuttle model" (ANSL)
proposed by Magistretti and collaborators [32] astrocytes respond to glutamatergic activation by increasing the rate of glucose utilization and the production of lactate which is released in the extracellular space through monocarboxylate transporters to be taken up by neurons (reviewed by [33] and references therein). Neurons can use both lactate and glucose as energetic substrates, and the issue of lactate versus glucose as energetic supply for neurons has been debated [34] .
Moreover, the CNS astrocytes represent the main storage site for glycogen [35] . Up to 40% of glucose entering astrocytes is metabolised into glycogen molecules which can be rapidly [40] . It is remarkable that most of the ATP produced within astrocytes is for cell pumping requirements to maintain ionic homeostasis [31] [72, 73] . The propagation of this signal is spatially and temporally connected with the activation of glucose uptake, which is also dependent on astrocyte glutamate transporters, thus allowing a concerted neurometabolic coupling between glucose utilization and neuronal activity [74] . [140] .
Evidence of genotype-phenotype correlation in
AxD is limited [141] . and in knock-in mice carrying the pathological gene mutations found in patients [149, 150] .
While these studies suggest that high levels of wild-type GFAP can reproduce the astrocyte phenotype of AxD, studies performed in cultured astrocytes showed that mutant GFAP protein accumulates more rapidly and at higher levels than the wild-type protein [151, 152] .
Thus, the precise mechanism through which 
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In cultured human and rat astrocytes MLC1
is localized along the plasma membrane, at astrocyte-astrocyte contacts and in many intracellular vesicles [170, 180, 181] . As for GFAP in AxD, MLC1 is an astrocyte specific protein not found in oligodendrocytes [174] [175] [176] compensates hyposmotic stress-induced cell swelling, including astrocyte swelling [184, 185] .
Hyposmotic shock is known to cause an abrupt, "foamy" cytoplasm [191, 192] . Poor astrogliosis and dysmorphic astrocytes [193] and that the few astrocytes present in these cultures had an abnormal morphology and composition of the intermediate filament network [190] . In the same study the role of eIF2B in astrocyte development was confirmed using RNA interference technology [190] . A detailed histopathological study revealed that in VWM brain tissue astrocytes show increased proliferation capacity, defective maturation and altered composition of the GFAP network with increased levels of the delta GFAP isoform and of the protein chaperon aB crystallin [194] . These results suggest that defects in astrocyte function may contribute to or directly cause white matter damage in VWM disease. Abnormal myelination and an early defect in glial cell proliferation and maturation have been observed in mice carrying an homozygous mutations in the eIF2B gene [195] . However, the presence of GFAP + cells in unaffected brain areas suggests that VWM pathogenesis can be the result of a complex interplay among different factors [194] . Studies performed in different cell culture systems, including those derived from patients, indicate that the decrease in eIF2B activity is more tightly related to alterations in the cellular stress response than to global protein synthesis inhibition. This could be due to the regulatory activity of eIF2B on endoplasmic reticulum stress response whose malfunctioning caused by gene mutations associated with VWM disease would lead to the generation of cells that are hyper-reactive to stress [196, 197] . In this pathological scenario, it remains to be explained why, despite eIF2B is ubiquitously brains [136] . Another recent study showed in the brain of VWM patients accumulation of the high molecular weight extracellular matrix component hyaluronan [198] , which inhibits oligodendrocyte and astrocyte progenitor cell differentiation [198] [199] [200] , further supporting the pathogenetic importance of abnormalities in glial cell maturation processes in this disease.
Lesson from cystic leukodystrophies
The study of cystic leukodystrophies has 
Concluding remarks and perspectives
During the past 20 years it has become clear that astrocytes exert complex and essential functions in the healthy CNS including regulation of synaptic transmission and information processing by neuronal circuits.
Recently, unexpected roles of astrocytes in higher brain functions such as learning and memory, sleep behaviour and regulation of breathing, have been described [205] [206] [207] . cell population [209, 210] , astrocytes are emerging as new potential pharmacological targets for CNS diseases [211] . The dissection of the molecular mechanisms of astrocyte reactivity is allowing identification of specific molecules whose function can be blocked or stimulated for therapeutic purposes [212, 214] . [226] . A better knowledge of astrocyte contribution to genetic leukodystrophies will help develop astrocytebased therapeutic strategies for these rare pathologies and for other neurological diseases.
